Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

12:57
11/17/19
11/17
12:57
11/17/19
12:57

The Medicines Co's ORION-10 study of Inclisiran met primary, secondary endpoints

The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol, or LDL-C, lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results were presented during a late-breaking science session at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. "Cumulative exposure to high LDL-C levels presents a significant risk of future heart attacks and strokes for millions of people, particularly those with ASCVD," said study principal investigator R. Scott Wright, M.D., Professor of Medicine, Consultant in Cardiology, Mayo Clinic in Rochester, Minnesota. "The data from ORION-10 show that inclisiran lowers LDL-C significantly and sustains reductions over a six-month period with a safety profile similar to placebo."

MDCO The Medicines Co.
$51.92

1.03 (2.02%)

10/02/19
RILY
10/02/19
NO CHANGE
Target $95
RILY
Buy
The Medicines Co. price target raised to $95 from $74 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for The Medicines Co. (MDCO) to $95 from $74 and added the shares to FBR's Alpha Generator List. The analyst has "heightened conviction" in inclisiran taking a dominant market share in the anti-PCSK9 marketplace, particularly at the expense of Regeneron's (REGN) Praluent. Mamtani's penetration-share scenario analysis suggests worldwide peak sales of $4.1B to $8.0B. The analyst keeps a Buy rating on The Medicines Co. The stock is yet to still reflect last week's "strong" Phase III Orion program execution and evidence generation on safety, efficacy, and durability of effect to reaffirm inclisiran's differentiated clinical profile, Mamtani tells nivestors in a research note.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $50
JEFF
Hold
The Medicines Co. downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded The Medicines Co. to Hold from Buy with a price target of $50, up from $44.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $50
JEFF
Hold
Jefferies downgrades The Medicines Co. on 'aggressive' inclisiran estimates
Jefferies analyst Biren Amin downgraded The Medicines Co. to Hold from Buy with a price target of $50, up from $44. After We conducting a doctor survey, the analyst thinks inclisiran consensus estimates are "too aggressive" and that The Medicines Co shares appear fully valued. While inclisiran leads in market share for PCSK9i, it is essentially split between inclisiran and Repath, Amin tell investors in a research note after polling 50 cardiologists. Based on the feedback, he lowered his 2026 inclisiran sales estimate to $1.4B from $1.7B, below the current consensus at $2.6B.
10/31/19
JEFF
10/31/19
NO CHANGE
Target $50
JEFF
Medicines Co. 'going concern' language introduces added risk, says Jefferies
Jefferies analyst Biren Amin said new disclosures in The Medicines Company's 10-Q regarding 2022 convertible notes introduces an additional risk as the company's balance sheet is not strong and if holders convert by December the company could require additional near-term funding. The 10-Q stated that if the notes are called and the company can't raise sufficient funds that "there is substantial doubt about the company's ability to continue as a going concern," Amin pointed out. He keeps a Hold rating on Medicines Co. shares.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
Agios Pharmaceuticals to hold an investor reception »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ARQL

ArQule

$9.67

0.15 (1.58%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
ArQule to hold an investor conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

THRM

Gentherm

$44.25

0.4 (0.91%)

07:54
12/09/19
12/09
07:54
12/09/19
07:54
Initiation
Gentherm initiated  »

Gentherm resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$59.85

0.28 (0.47%)

07:53
12/09/19
12/09
07:53
12/09/19
07:53
Recommendations
TJX analyst commentary  »

TJX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$25.55

0.73 (2.94%)

07:51
12/09/19
12/09
07:51
12/09/19
07:51
Downgrade
Investar Holding rating change  »

Investar Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$39.58

0.86 (2.22%)

07:50
12/09/19
12/09
07:50
12/09/19
07:50
Downgrade
FB Financial rating change  »

FB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$353.99

8.295 (2.40%)

07:49
12/09/19
12/09
07:49
12/09/19
07:49
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$233.74

0.3 (0.13%)

, BGNE

BeiGene

$186.89

-2.3 (-1.22%)

07:47
12/09/19
12/09
07:47
12/09/19
07:47
Recommendations
Amgen, BeiGene analyst commentary  »

Amgen price target raised…

AMGN

Amgen

$233.74

0.3 (0.13%)

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

, SCHW

Charles Schwab

$48.95

0.22 (0.45%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Downgrade
TD Ameritrade, Charles Schwab rating change  »

TD Ameritrade shares…

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

SCHW

Charles Schwab

$48.95

0.22 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$3.86

0.025 (0.65%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Hot Stocks
Mustang Bio: Lentiviral gene therapy with busulfan conditioning 'well tolerated' »

Mustang Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Recommendations
Bluebird Bio analyst commentary  »

Bluebird Bio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

, AR

Antero Resources

$2.18

0.09 (4.31%)

07:43
12/09/19
12/09
07:43
12/09/19
07:43
Hot Stocks
Antero Midstream to purchase $100M of shares from Antero Resources »

Antero Midstream (AM)…

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

AR

Antero Resources

$2.18

0.09 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCN

FTI Consulting

$111.68

0.28 (0.25%)

07:42
12/09/19
12/09
07:42
12/09/19
07:42
Hot Stocks
FTI Consulting enters partnership with Brainspace »

FTI Consulting announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$33.03

0.8 (2.48%)

07:41
12/09/19
12/09
07:41
12/09/19
07:41
Hot Stocks
BridgeBio appoints Eli Wallace as chief scientific officer for oncology »

BridgeBio Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

07:40
12/09/19
12/09
07:40
12/09/19
07:40
Recommendations
Alphabet Class A analyst commentary  »

Alphabet shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
12/09/19
12/09
07:40
12/09/19
07:40
General news
Treasury Market Outlook: equities have dipped lower in quiet trade »

Treasury Market Outlook:…

EPD

Enterprise Products

$26.25

0.18 (0.69%)

, ENB

Enbridge

$38.52

0.015 (0.04%)

07:39
12/09/19
12/09
07:39
12/09/19
07:39
Hot Stocks
Enterprise Products, Enbridge sign LOI to jointly develop deepwater terminal »

Enterprise Products…

EPD

Enterprise Products

$26.25

0.18 (0.69%)

ENB

Enbridge

$38.52

0.015 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

BLK

BlackRock

$495.78

5.6 (1.14%)

07:39
12/09/19
12/09
07:39
12/09/19
07:39
Conference/Events
BlackRock management to meet with Oppenheimer »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 26

    Feb

HBIO

Harvard Bioscience

$2.95

0.01 (0.34%)

07:38
12/09/19
12/09
07:38
12/09/19
07:38
Downgrade
Harvard Bioscience rating change  »

Harvard Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.19

-0.01 (-0.84%)

07:37
12/09/19
12/09
07:37
12/09/19
07:37
Hot Stocks
Sesen Bio initiates rolling submission of BLA for Vicinium to FDA »

Sesen Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$59.81

0.89 (1.51%)

07:36
12/09/19
12/09
07:36
12/09/19
07:36
Conference/Events
Brunswick management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SSKN

Strata Skin Sciences

$2.16

(0.00%)

07:36
12/09/19
12/09
07:36
12/09/19
07:36
Initiation
Strata Skin Sciences initiated  »

Strata Skin Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Dec

AUB

Atlantic Union Bankshares

$37.82

0.45 (1.20%)

07:35
12/09/19
12/09
07:35
12/09/19
07:35
Conference/Events
Atlantic Union Bankshares management to meet with Compass Point »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ENB

Enbridge

$38.52

0.015 (0.04%)

, EPD

Enterprise Products

$26.25

0.18 (0.69%)

07:35
12/09/19
12/09
07:35
12/09/19
07:35
Hot Stocks
Enbridge, Enterprise Products to jointly develop crude oil export terminal »

Enbridge (ENB) and…

ENB

Enbridge

$38.52

0.015 (0.04%)

EPD

Enterprise Products

$26.25

0.18 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.